The public consultation by European Commission

As part of the evaluation of the EU Drugs Strategy (2013-20) and EU Action Plan on Drugs (2017-20), the European Commission has launched the public consultation.

Target audience

The Commission seeks to gather input from a broad range of stakeholders, including public authorities and administrations at national, regional and local levels including customs and law enforcement, academia, anti-drugs and health related civil society and non-governmental organisations, chemical and medical industry representatives, practitioners involved in the drugs or health policy fields and private individuals.
Anyone affected by illicit drug use is especially welcome to respond to this public consultation.

The objective

The objective of this consultation is to gather stakeholders’ feedback on the EU Drugs Strategy 2013-2020 and the EU Action Plan on Drugs 2017-2020, as they are approaching the end of their cycle.
The consultation addresses all main policy areas of the Drugs Strategy, including drug demand and drug supply reduction and three cross-cutting themes, namely coordination, international cooperation and information, research and evaluation. Similar to the entire evaluation exercise, the consultation looks at the effectiveness, efficiency, relevance and coherence of the actions undertaken to cover the areas mentioned, as well as at the achieved EU added value.
A synopsis of the responses received will be included in the Staff Working Document that will be produced to summarise the findings of the evaluation. The final results of the evaluation will be used by the European Commission, the European Parliament, the Council and Member States in the future decision-making process regarding drug policy.

The consultation is available in all EU languages, and is open until 4 February 2020 here.

More details – here.

No Comments

Post a Comment